Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi).
Clin Vaccine Immunol. 2007 Oct; 14(10):1307-10.CV

Abstract

The use of human sera collected from individuals of known infected and noninfected status is necessary for the validation of diagnostic assays and for the determination of cutoff values. However, the routine inclusion of pooled human sera from infected individuals for use as positive controls in commercial assay kits has many disadvantages. Sufficient quantities of sera can be difficult to obtain, and there are ethical and safety issues to be considered. Additionally, each batch of control material requires standardization, as each will differ in antibody titer. We have genetically engineered chimeric immunoglobulin G (IgG), IgM, and IgA antibodies consisting of mouse-derived variable regions and human constant regions derived from peripheral blood lymphocytes. The chimeric nature of these antibodies allows the desired antigen specificity created through mouse immunization and hybridoma technology while retaining a human constant region required for recognition by the enzyme-conjugated antihuman signal antibody. We have investigated the potential use of chimeric IgG with specificity for the major surface antigen of Orientia tsutsugamushi as an alternative positive control for inclusion in a commercial enzyme-linked immunosorbent assay kit for the diagnosis of rickettsia scrub typhus (caused by infection with O. tsutsugamushi). Chimeric IgG was expressed in stably transfected CHO cells, allowing production of unlimited quantities. The purified protein was found to have a much greater specificity for the scrub typhus antigen than the serum-derived controls. The methods described could be applied to other assay kits for the detection of antibodies against infectious agents.

Links

PMC Free PDF

PMC Free Full Text

FREE Publisher Full Text

Authors+Show Affiliations

Jones ML

School of Molecular and Microbial Sciences, University of Queensland, St. Lucia 4072, QLD, Australia. martina.jones@uq.edu.au

Barnard RT

No affiliation info available

MeSH

AnimalsAntibodies, BacterialCross ReactionsEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin GMiceMutant Chimeric ProteinsOrientia tsutsugamushiScrub Typhus

Pub Type(s)

Journal Article

Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17687111

Citation

Jones, Martina L., and Ross T. Barnard. "Use of Chimeric Antibodies as Positive Controls in an Enzyme-linked Immunosorbent Assay for Diagnosis of Scrub Typhus (infection By Orientia Tsutsugamushi)." Clinical and Vaccine Immunology : CVI, vol. 14, no. 10, 2007, pp. 1307-10.

Jones ML, Barnard RT. Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi). Clin Vaccine Immunol. 2007;14(10):1307-10.

Jones, M. L., & Barnard, R. T. (2007). Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi). Clinical and Vaccine Immunology : CVI, 14(10), 1307-10.

Jones ML, Barnard RT. Use of Chimeric Antibodies as Positive Controls in an Enzyme-linked Immunosorbent Assay for Diagnosis of Scrub Typhus (infection By Orientia Tsutsugamushi). Clin Vaccine Immunol. 2007;14(10):1307-10. PubMed PMID: 17687111.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi). AU - Jones,Martina L, AU - Barnard,Ross T, Y1 - 2007/08/08/ PY - 2007/8/10/pubmed PY - 2007/11/14/medline PY - 2007/8/10/entrez SP - 1307 EP - 10 JF - Clinical and vaccine immunology : CVI JO - Clin Vaccine Immunol VL - 14 IS - 10 N2 - The use of human sera collected from individuals of known infected and noninfected status is necessary for the validation of diagnostic assays and for the determination of cutoff values. However, the routine inclusion of pooled human sera from infected individuals for use as positive controls in commercial assay kits has many disadvantages. Sufficient quantities of sera can be difficult to obtain, and there are ethical and safety issues to be considered. Additionally, each batch of control material requires standardization, as each will differ in antibody titer. We have genetically engineered chimeric immunoglobulin G (IgG), IgM, and IgA antibodies consisting of mouse-derived variable regions and human constant regions derived from peripheral blood lymphocytes. The chimeric nature of these antibodies allows the desired antigen specificity created through mouse immunization and hybridoma technology while retaining a human constant region required for recognition by the enzyme-conjugated antihuman signal antibody. We have investigated the potential use of chimeric IgG with specificity for the major surface antigen of Orientia tsutsugamushi as an alternative positive control for inclusion in a commercial enzyme-linked immunosorbent assay kit for the diagnosis of rickettsia scrub typhus (caused by infection with O. tsutsugamushi). Chimeric IgG was expressed in stably transfected CHO cells, allowing production of unlimited quantities. The purified protein was found to have a much greater specificity for the scrub typhus antigen than the serum-derived controls. The methods described could be applied to other assay kits for the detection of antibodies against infectious agents. SN - 1556-6811 UR - https://www.unboundmedicine.com/medline/citation/17687111/Use_of_chimeric_antibodies_as_positive_controls_in_an_enzyme_linked_immunosorbent_assay_for_diagnosis_of_scrub_typhus__infection_by_Orientia_tsutsugamushi__ L2 - http://cvi.asm.org/cgi/pmidlookup?view=long&pmid=17687111 DB - PRIME DP - Unbound Medicine ER -

Tags

Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi).Clin Vaccine Immunol. 2007 Oct; 14(10):1307-10.CV